What did @kristisawicki actually say?
She said that anyone considering peptide therapy should first run a broad panel of baseline labs, including a CBC, CMP, fasting metabolic markers, lipid panel with ApoB, CRP, hormone panels for both sexes, thyroid function, micronutrients, and IGF-1 for growth hormone-related peptides. She also recommended checking prolactin and an omega-3 index for specific concerns.
Her framing was reasonable throughout. She described labs as a starting point for "pattern recognition and monitoring things over time," not as a gating checklist that guarantees peptide safety. She was careful to say this is educational, and she pointed people toward working with a doctor or ordering through a service like Function Health. That is a more measured position than many creators in this space take.
Worth noting: she mentioned "coaching" people, which sits in an ambiguous space. A PhD in longevity or performance science does not equal a clinical license, and that distinction matters when lab interpretation drives intervention decisions.
Does the science back this up?
Mostly, yes. The general principle of establishing metabolic and organ-function baselines before initiating any therapy that interacts with hormonal or inflammatory pathways is well-supported. The specific markers she chose are defensible, though some are better supported than others.
ApoB over LDL-C is one of her stronger recommendations. Sniderman et al. (2019, JAMA Cardiology) showed ApoB is a more consistent predictor of atherosclerotic risk than LDL-C alone, particularly in people with metabolic syndrome. That is a legitimate upgrade from a standard lipid panel.
Her push for RBC magnesium over serum magnesium is also correct. Serum magnesium reflects roughly 1% of total body magnesium and can appear normal even in states of functional deficiency (Workinger et al., 2018, Nutrients).
The IGF-1 baseline recommendation for growth hormone secretagogues like CJC-1295 or ipamorelin is clinically appropriate. IGF-1 is the primary downstream marker used to monitor GH axis activity, and running it before and during therapy is standard practice in endocrinology (Molitch et al., 2011, Journal of Clinical Endocrinology and Metabolism).
What did they get wrong (or right)?
She got the fundamentals right. The liver and kidney function argument for any compound that influences metabolism or inflammation is not overcautious, it is basic pharmacology. If clearance organs are compromised before you add a bioactive peptide, you have compounded uncertainty, not optimized it.
One error worth flagging: she referred to "HPA1C" when she almost certainly meant HbA1c (hemoglobin A1c). HPA axis is the hypothalamic-pituitary-adrenal stress system, a completely different thing. That kind of slip is minor but reflects the audio-over-accuracy problem common to TikTok health content.
She also said peptides "interact with nutrient sensing and insulin signaling" as a blanket statement. This is true for some peptides, particularly GLP-1-adjacent compounds and certain growth hormone secretagogues, but it is not a universal property of all peptides she listed in her category. Generalizing across BPC-157, TB-500, GHK-Cu, and MK-677 as if they share the same metabolic fingerprint is imprecise.
The TPO antibodies recommendation (she called them "CPO antibodies," likely a verbal slip) for thyroid is legitimate. Hashimoto's is underdiagnosed and can produce symptoms that look like fatigue, poor recovery, or hormonal disruption, exactly the problems people bring to longevity coaches.
What should you actually know?
A comprehensive baseline panel before any hormonal or peptide-based intervention is good practice. The markers she listed align with what functional medicine physicians and endocrinologists use before initiating therapy that touches the GH axis, thyroid, or metabolic pathways. That part is not controversial.
What she did not say, and what matters: a panel does not make peptides safe. Several of the compounds in her category, including MK-677 and CJC-1295 with DAC, carry real risks including fluid retention, insulin resistance, and potential IGF-1 elevation beyond normal physiological ranges. Labs tell you where you started. They do not prevent adverse outcomes mid-therapy without ongoing monitoring.
She mentioned ordering through Function Health as an option. Direct-to-consumer lab testing is legal and increasingly common, but interpretation without clinical context has limits. An out-of-range ferritin, for example, means something very different in a 28-year-old woman with heavy periods than in a 55-year-old man with no known cause. Pattern recognition, as she correctly said, requires clinical judgment, not just data.
If you are seriously considering peptide therapy, this lab list is a reasonable starting document. Use it as a conversation framework with a licensed provider, not as a self-authorization checklist.